



Monaldi Archives for Chest Disease

eISSN 2532-5264

<https://www.monaldi-archives.org/>

Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid dissemination of science. The **Early Access** service lets users access peer-reviewed articles well before print / regular issue publication, significantly reducing the time it takes for critical findings to reach the research community.

These articles are searchable and citable by their DOI (Digital Object Identifier).

The **Monaldi Archives for Chest Disease** is, therefore, e-publishing PDF files of an early version of manuscripts that have undergone a regular peer review and have been accepted for publication, but have not been through the typesetting, pagination and proofreading processes, which may lead to differences between this version and the final one.

The final version of the manuscript will then appear in a regular issue of the journal.

E-publishing of this PDF file has been approved by the authors.

All legal disclaimers applicable to the journal apply to this production process as well.

Monaldi Arch Chest Dis 2024 [Online ahead of print]

To cite this Article:

Rathi V. **Comments on “Comparative yield of transbronchial cryo-nodal biopsy, transbronchial intra-nodal forceps biopsy, and transbronchial needle aspiration for mediastinal lesions at a tertiary care center in India (COLD-FORCEPS study)”**. *Monaldi Arch Chest Dis* doi: 10.4081/monaldi.2024.2918

 ©The Author(s), 2024
Licensee [PAGEPress](#), Italy

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.



Comments on “Comparative yield of transbronchial cryo-nodal biopsy, transbronchial intra-nodal forceps biopsy, and transbronchial needle aspiration for mediastinal lesions at a tertiary care center in India (COLD-FORCEPS study)”

Vidushi Rathi

Department of Pulmonary Medicine, VPCI, University of Delhi, New Delhi, India

Correspondence: Vidushi Rathi, Department of Pulmonary Medicine, VPCI, University of Delhi, Vijay Nagar Marg, New Delhi, 110007, India.

Tel.: +91-0-9971891536.

E-mail: vidushirathi@gmail.com.

Key words: EBUS, cryobiopsy, guidelines.

Conflict of interest: the author declares that she has no competing interests, and all authors confirm accuracy.

Ethics approval and consent to participate: this is a letter where no patient data was recorded. Thus, ethical approval is not applicable/required.

Patient consent for publication: not applicable.

Funding: none.

Availability of data and materials: no new clinical data of patients in this letter.

Dear Editor,

The recent study by Madan et al. [1] provides valuable information on the utility of intranodal cryobiopsy or forceps to endobronchial ultrasound - transbronchial needle aspiration (EBUS-TBNA) during sampling of mediastinal lymph nodes. It found that intranodal cryoprobe acquires a larger tissue and increases diagnostic yield. However, the increase in the diagnostic yield was statistically not significant. This is an important observation. Often, pilot studies with small sample size find significant differences between two procedures which larger studies fail to find. However, finding an insignificant advantage of intranodal cryobiopsy to EBUS-TBNA raises the doubt whether larger studies would change this observation.

Diagnostic utility of cryobiopsy has gained traction over time with increasing evidence supporting its benefits. A systematic review and meta-analysis of 39 studies published in 2022 on the diagnostic yield of cryobiopsy for peripheral pulmonary lesions (PPLs), interstitial lung diseases (ILDs), and lung cancers found a significantly greater yield with a larger tissue size [2]. None of the over 3500 biopsies included in the meta-analysis included mediastinal lymph node sampling by intranodal cryobiopsy.

A randomized trial of 197 patients [3] has found that cryobiopsy of mediastinal lymph nodes improves the yield of diagnosis of benign lesions and uncommon tumors, whereas for common lung malignancies and diagnosis of metastatic lymphadenopathy, there yield is similar to EBUS-TBNA. This again emphasizes the use of cryobiopsy can help us to possibly increase the yield when a benign etiology like tuberculosis or sarcoidosis is suspected. This is of immense importance in developing countries, where the diagnostic dilemma of underlying tuberculosis in any sarcoidosis patient remains unclear. Larger studies for cryobiopsy in mediastinal lymphadenopathy in this subgroup of patients are required to provide more evidence.

A recently published randomized study [4] comparing cryobiopsy and forceps biopsy with EBUS-TBNA had also found a similar yield with all three modalities. The observation resonates with that made by Manu et al [1]. However, they found that cryobiopsy yielded larger tissue sizes. This has a particular advantage in conditions like lung cancer. Smaller tissues from EBUS-TBNA with or without intranodal forceps often get consumed during histopathological and/or immunohistochemistry analysis. This leaves no or inadequate tissue for conducting molecular analysis. As the target gene library to which pharmacotherapy is approved increases, so does the size of the tissue required for molecular analysis. In case of inadequate tissue, either a repeat sampling is required or less reliable methods like blood biopsy are resorted to. Cryobiopsy, by yielding tissue of larger sizes, becomes clearly advantageous in terms of yield and procedure time compared to EBUS-TBNA alone or forceps biopsy.

The work by Manu et al provides evidence that intranodal forceps biopsy at present does not have a statistically significant benefit. Similarly, adding cryobiopsy to EBUS-TBNA may not

increase the diagnostic yield of mediastinal lymph node sampling compared to EBUS-TBNA alone. However, the addition of cryobiopsy to EBUS-TBNA has an advantage in suspected neoplastic lymphadenopathy. It provides a larger tissue sample that can be subjected to molecular testing for immunotherapy or targeted therapy and avoiding the need for a repeat biopsy.

The current national guidelines recommend cryobiopsy for mediastinal lymphadenopathy in patients with negative previous EBUS-TBNA or negative onsite pathological examination. [5] There is no mention of the underlying etiology (benign vs malignant) suspected in the recommendations.

Thus, as the emerging evidence in recent studies is not very robust, the indication of cryobiopsy of mediastinal lymphadenopathy remains unclear and should be individualized.

References

1. Madan M, Mahendran AJ, Kumar R, et al. Comparative yield of transbronchial cryonodal biopsy, transbronchial intra-nodal forceps biopsy, and transbronchial needle aspiration for mediastinal lesions at a tertiary care center in India (COLD-FORCEPS study). *Monaldi Arch Chest Dis* 2024; doi: 10.4081/monaldi.2024.2813.
2. Giri M, Huang G, Puri A, et al. Efficacy and safety of cryobiopsy vs. forceps biopsy for interstitial lung diseases, lung tumors, and peripheral pulmonary lesions: an updated systematic review and meta-analysis. *Front Med (Lausanne)* 2022;9:840702.
3. Zhang J, Guo JR, Huang ZS, et al. Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial. *Eur Respir J* 2021;58:2100055.
4. Cheng TL, Huang ZS, Zhang J, et al. Comparison of cryobiopsy and forceps biopsy for the diagnosis of mediastinal lesions: a randomised clinical trial. *Pulmonology* 2024; doi: 10.1016/j.pulmoe.2023.12.002.
5. Mohan A, Madan K, Hadda V, et al. Guidelines for endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA): Joint Indian Chest Society (ICS)/Indian Association for Bronchology (IAB) recommendations. *Lung India* 2023;40:368-400.